Abstract 917P
Background
Patients with oral cavity squamous cell carcinoma (OCSCC) are at high risk of death within 5 years of treatment. Previous works have demonstrated that spatial arrangement of tumor-infiltrating lymphocytes (TILs) and surrounding nuclei (e.g, cancer nuclei, macrophages, fibroblasts) is prognostic of overall survival (OS) in different types of cancer, including oropharyngeal and laryngeal. In this work, we evaluated the prognostic ability of a computerized strategy that characterizes the spatial arrangement of TILs & non-TILs on digitized H&E-stained slides of patients with OCSCC.
Methods
Whole slide images (WSIs) from a cohort of 283 patients with OCSCC were retrospectively collected from the Cancer Genome Atlas (TCGA, D1). Additionally, WSIs from 136 patients with OCSCC were obtained from Vanderbilt University Medical Center (VUMC, D2). D1 was used to train a prognostic model while D2 was used for independent validation. Computer algorithms automatically identified 2 types of nuclei (TILs & non-TILs) and built clusters for each nucleus type based on proximity. Metrics related to density, intersection, and neighborhood were computed from these clusters. A proportional hazard Cox regression model, regularized via the least absolute shrinkage and selection operator, was trained to predict risk of death. The percentile 66 risk score on D1 was used as a threshold for stratifying patients on D2 as either low or high risk. Survival analysis was then used to evaluate the association with OS.
Results
Patients in D2 defined as “low risk” (57%) based on spatial arrangement of TILs has significantly better OS than those identified as “high risk” (43%) with hazard ratio=3.84 (95% confidence interval: 1.39-10.6, p<0.01). Multivariable survival analysis showed that this model was prognostic independent of age and overall, T, and N stages with HR=2.88 (95% CI: 1.10-7.56, p=0.03).
Conclusions
A computerized image analysis model based on measurements of spatial arrangement of TILs & non-TILs was found to be prognostic in patients with OCSCC. With more modeling and development, this model may provide a risk classifier for use in routine clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Madabhushi.
Funding
US National Institutes of Health, US Department of Defense.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03